The two vaccines that are in a close contest to emerge as the world's first silver bullet against COVID-19 are: candidates of Pfizer-BioNtech and Oxford University-AstraZeneca. The roll-out would depend on the safety efficacy data of phase 3 trials which both the developers are expected to release next month.